INSUBCONTINENT EXCLUSIVE:
investing, but investors in Beijing and Shanghai are now increasingly leading the largest deals for US life science and biotech
venture investment ever, with over one hundred companies receiving $4 billion in investment.As Chinese investors continue to shift their
strategies towards life science and biotech, China is emphatically positioning itself to be a leader in medical investing with a growing
become its second biggest investment area, with life science and biotech companies accounting for nearly 30% of its investing activity in
roughly 70% of its deals in the past two years focusing on cancer detection and treatment.That is driven in part by investments like the
international footprints and learnings from across the globe.Founded as a joint-venture offshoot between US-based Juno Therapeutics and
focused on the next-generation of cell-based immunotherapy cancer treatments using chimeric antigen receptor T-cell (CAR-T) technologies
Li was also once a partner at the Silicon Valley brand-name investor, Kleiner Perkins.JW embodies the benefits that can come from importing
cross-border investment and import regulations in China have improved
As such, Chinese venture firms are now increasingly searching for innovation abroad, looking to capitalize on expanding opportunities in the
more mature US medical industry that can offer innovative technologies and advanced processes that can be brought back to the East.In April,
Qiming Venture Partners, another Chinese venture titan, closed a $120 million fund focused on early-stage US healthcare
Qiming has been ramping up its participation in the medical space, investing in 24 companies over the 2017-18 period.New firms diving into
VCs who can find the best medical startups and have a growing influence on the flow of venture dollars in the US.At the top of the list is
investments focusing on anything from real-time patient care insights to antibody and therapeutic technologies for cancer and
participating in deals that total over a billion dollars in aggregate funding.Backed by the efforts of Yeshwant and select others, the
same vein, life science and health investing has been part of the lifeblood for some major US funds including Founders Fund, which has
consistently dedicated over 25% of its deployed capital to the space since at least 2015.The tides may be changing, however, as the recent
expansion of oversight for the Committee on Foreign Investment in the United States (CFIUS) may severely impact the flow of Chinese capital
involving a foreign entity related to the production, design or testing of technology that falls under a list of 27 critical industries,
including biotech research and development.The true implications of the expanded rules will depend on how aggressively and how often CFIUS
and when patients are finally seen, they are frequently met by overworked or inexperienced medical staff, rushing to get people in and out
ineffective, as import laws and affordability issues made many globally approved drugs unavailable.As one would assume, poor detection and
discovered months prior and swept under the rug.Fracturing public trust around medical treatment has serious, potentially destabilizing
innovation by rolling out policies that improve the chances of success for health startups, while reducing costs and risk for
investors.Billions of public investment flooded into the life science sector, and easier approval processes for patents, research grants,
capitalists, on top of financial incentives and a higher-growth local medical sector, loosening of drug import laws opened up opportunities
Liquidity has also improved due to swelling global interest in healthcare
Plus, the Hong Kong Stock Exchange recently announced changes to allow the listing of pre-revenue biotech companies.The changes implemented
and others, have made many US investors weary of investing in life science companies overseas.And with the Valley similarly stepping up its
focus on startups that sprout from the strong American university system, bubbling valuations have started to raise concern.But with China
itself as the next leader in international health innovation.
